4SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…